Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Willan

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Journal of Chronic Diseases|January 1, 1983
Relative efficiency in survival analysisA R Willan
Controlled Clinical Trials|June 1, 2001
Analysis, sample size, and power for estimating incremental net health benefit from clinical trial dataA R Willan
Controlled Clinical Trials|June 1, 1994
Power function arguments in support of an alternative approach for analyzing management trialsA R Willan
Biometrics|March 1, 1988
Using the maximum test statistic in the two-period crossover clinical trialA R Willan
Lancet (London, England)|August 23, 2001
Broad-spectrum antibiotics in ORACLEA R Willan
BMC Medical Research Methodology|November 1, 2001
On the probability of cost-effectiveness using data from randomized clinical trialsA R Willan
Statistics in Medicine|June 8, 2001
Incremental net benefit in randomized clinical trialsA R Willan, D Y Lin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1984
Methodologic issues in trials of antiemeticsJ L Pater, A R Willan
Controlled Clinical Trials|June 1, 1984
Clinical trials as diagnostic testsJ L Pater, A R Willan
Biometrics|September 1, 1986
Carryover and the two-period crossover clinical trialA R Willan, J L Pater
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Journal of Chronic Diseases|January 1, 1983
Relative efficiency in survival analysisA R Willan
Controlled Clinical Trials|June 1, 2001
Analysis, sample size, and power for estimating incremental net health benefit from clinical trial dataA R Willan
Controlled Clinical Trials|June 1, 1994
Power function arguments in support of an alternative approach for analyzing management trialsA R Willan
Biometrics|March 1, 1988
Using the maximum test statistic in the two-period crossover clinical trialA R Willan
Lancet (London, England)|August 23, 2001
Broad-spectrum antibiotics in ORACLEA R Willan
BMC Medical Research Methodology|November 1, 2001
On the probability of cost-effectiveness using data from randomized clinical trialsA R Willan
Statistics in Medicine|June 8, 2001
Incremental net benefit in randomized clinical trialsA R Willan, D Y Lin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1984
Methodologic issues in trials of antiemeticsJ L Pater, A R Willan
Controlled Clinical Trials|June 1, 1984
Clinical trials as diagnostic testsJ L Pater, A R Willan
Biometrics|September 1, 1986
Carryover and the two-period crossover clinical trialA R Willan, J L Pater
Pageof 8